ClinicalTrials.gg
CompletedNCT00175903Updated Mar 17, 2015

Levetiracetam Versus Standard Antiepileptic Drugs (Carbamazepine and Valproate) Used as Monotherapy in Patients With Newly Diagnosed Epilepsy

A Phase 3 interventional study of Levetiracetam and Carbamazepine Controlled Release (CBZ-CR) in Epilepsy, sponsored by UCB Pharma. Completed at 231 sites in 24 countries. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2015-03-17.

Sponsored by UCB Pharma (part of UCB S.A.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,701
Allocation
Randomized
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 60 studies testing levetiracetam in Epilepsy — 4 open to participants now, 4 under way, 2 of them phase 3. Levetiracetam · Epilepsy.

Enrollment
Largest of 60
1,701 · median 94
Started
2005
with 4 others
Phase 3
28 of 60
2 open now
Registered
10th of 60
by date
Lead sponsor
23 of 60
UCB Pharma

Among the 60 studies testing levetiracetam in Epilepsy, this one has the largest enrollment, is one of 5 that started in 2005, is one of 28 in phase 3, and was the 10th registered.

Epilepsy

1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.

Browse Epilepsy studies →

Open to participants now

4 of the 60 studies testing levetiracetam in Epilepsy are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About levetiracetam

Levetiracetam: first FDA approval 1999 (KEPPRA), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 284 Epilepsy studies recruiting now, 114 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies testing levetiracetam in Epilepsy, or all of them as a file.
02

Study summary

Study N01175 was to compare overall effectiveness (efficacy and safety) of levetiracetam (LEV) versus the 2 older antiepileptic drugs (AEDs), sodium valproate extended release (VPA-ER) and carbamazepine controlled release (CBZ-CR) in the treatment of subjects with newly diagnosed epilepsy.

03

Conditions studied

  • Epilepsy

Browse trials for

Keywords

  • Newly Diagnosed Epilepsy
  • Levetiracetam
  • Keppra
  • Carbamazepine
  • Valproate
04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of epilepsy (all types of seizures) was made during the past year
  • Subjects must have had at least two unprovoked seizures in the past 2 years with at least one during the last 6 months
  • Female subjects without are eligible. Female subjects with childbearing potential are eligible if they use a medically accepted method

Exclusion criteria

Exclusion Criteria:

  • Subjects previously allocated to a trial treatment (CBZ, VPA and LEV) used in this trial
  • Participation in another clinical trial with an drug or device within 12 weeks of the selection visit (V1), or at any time during this trial
  • Pregnant or lactating women
  • Presence of known pseudoseizures within the last year
  • Uncountable seizures (clusters) or history of convulsive status epilepticus
  • Any disorder or condition that may interfere with the absorption, distribution, metabolisation or excretion of drugs
  • History of suicide attempt, current suicidal ideation, or other serious psychiatric disorders requiring or having required hospitalization or medication within the previous five years
  • Presence of progressive cerebral disease, any other progressively degenerative neurological disease, or any cerebral tumors
  • Presence of a terminal illness or any medical condition that might interfere with the subject's trial participation
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,701 participants (actual)

Study arms

  • Experimental
    Levetiracetam

    Daily dose of 1000 to 3000 mg film-coated oral tablets, 250-500 mg twice daily.

    Drug: Levetiracetam

  • Active comparator
    Older Antepileptic Drugs

    Older AEDs consist of CBZ-CR 200 mg and 400 mg and VPA-ER 300 mg and 500 mg.

    Drug: Carbamazepine Controlled Release (CBZ-CR) · Drug: Valproate Extended Release

Interventions

  • Daily dose of 1000 to 3000 mg film-coated oral tablets, 250-500 mg twice daily.

  • DrugCarbamazepine Controlled Release (CBZ-CR)

    Daily dose of 600-1600 mg CR oral tablets, 200 mg and 400 mg twice daily.

  • Daily dose of 1000-2000 mg ER oral tablets, 300 mg and 500 mg twice daily.

06

What researchers measure

Primary outcomes

  1. Time to withdrawal from study medication (starting at V1) as a measure of combined efficacy and safety

    Time frame: Visit 1 to End of Study (approximately 52 weeks)

Secondary outcomes

  1. The time to withdrawal comparing Levetiracetam versus the older Antiepileptic Drugs based on the subset of subjects whose best recommended treatment was Carbamazepine Controlled Release or Sodium Valproate Extended Release

    Time frame: Visit 1 to End of Study (approximately 52 weeks)

  2. The retention rate after 6 months comparing Levetiracetam versus the older Antiepileptic Drugs

    Time frame: Visit 1 to Visit 4 (approximately 26 weeks)

  3. The retention rate after 12 months comparing Levetiracetam versus the older Antiepileptic Drugs

    Time frame: Visit 1 to Visit 5 (approximately 52 weeks)

  4. The retention rate after 6 months comparing Levetiracetam versus older Antiepileptic Drugs based on the subset of subjects whose best recommended treatment was Carbamazepine Controlled Release or Sodium Valproate Extended Release

    Time frame: Visit 1 to Visit 4 (approximately 26 weeks)

  5. The retention rate after 12 months comparing Levetiracetam versus older Antiepileptic Drugs based on the subset of subjects whose best recommended treatment was Carbamazepine Controlled Release or Sodium Valproate Extended Release

    Time frame: Visit 1 to Visit 5 (approximately 52 weeks)

  6. Seizure freedom at 6 months comparing Levetiracetam versus older Antiepileptic Drugs

    Time frame: Visit 1 to Visit 4 (approximately 26 weeks)

  7. Seizure freedom at 12 months comparing Levetiracetam versus older Antiepileptic Drugs

    Time frame: Visit 1 to Visit 5 (approximately 52 weeks)

  8. Seizure freedom at 6 months comparing Levetiracetam versus older Antiepileptic Drugs based on based on the subset of subjects whose best recommended treatment was Carbamazepine Controlled Release or Sodium Valproate Extended Release

    Time frame: Visit 1 to Visit 4 (approximately 26 weeks)

  9. Seizure freedom at 12 months comparing Levetiracetam versus older Antiepileptic Drugs based on based on the subset of subjects whose best recommended treatment was Carbamazepine Controlled Release or Sodium Valproate Extended Release

    Time frame: Visit 1 to Visit 5 (approximately 52 weeks)

  10. Time to first seizure comparing Levetiracetam versus older Antiepileptic Drugs

    Time frame: Visit 1 to End of Study (approximately 52 weeks)

  11. Time to first seizure comparing Levetiracetam versus older Antiepileptic Drugs based on the subset of subjects whose best recommended treatment was Carbamazepine Controlled Release or Sodium Valproate Extended Release

    Time frame: Visit 1 to End of Study (approximately 52 weeks)

07

Study locations

231 sites
  • Adelaide, Australia
  • Bedford Park, Australia
  • Brisbane, Australia
  • Cairns, Australia
  • Camperdown, Australia
  • Chatswood, Australia
  • Clayton, Australia
  • Maroochydore, Australia
  • Parkville, Australia
  • Perth, Australia
  • Randwick, Australia
  • West Heidelberg, Australia
  • Graz, Austria
  • Innsbrick, Austria
  • Klagenfurt, Austria
  • Linz, Austria
  • Steyr, Austria
  • Vienna, Austria
  • Brugge, Belgium
  • Dendermonde, Belgium
  • Edegem, Belgium
  • Gent, Belgium
  • Haine St Paul, Belgium
  • Jette, Belgium
  • Kortrijk, Belgium
  • Leuven, Belgium
  • Oostende, Belgium
  • Ottignies, Belgium
  • Plovdiv, Bulgaria
  • Sofia, Bulgaria
  • Varna, Bulgaria
  • Litomysl, Czech Republic
  • Ostrava-Poruba, Czech Republic
  • Zlin, Czech Republic
  • Aalborg, Denmark
  • Copenhagen, Denmark
  • Holbaek, Denmark
  • Holstebro, Denmark
  • Hus (Helsinki), Finland
  • Kuopio, Finland
  • Tampere, Finland
  • Blaye, France
  • Bordeaux, France
  • Brest, France
  • Carcassonne, France
  • Cherbourg, France
  • Colmar, France
  • Creil, France
  • Dijon, France
  • Freyming Merlebach, France
  • Grenoble Cedex 9, France
  • La Seyne Sur Mer, France
  • Lille, France
  • Lyon, France
  • Marseille, France
  • Mulhouse, France
  • Nancy, France
  • Nimes, France
  • Paris, France
  • Rennes, France
  • Roanne, France
  • Saint Brieuc, France
  • Saint Quentin, France
  • Toulouse Cedex 04, France
  • Valenciennes, France
  • Vesoul, France
  • Altenburg, Germany
  • Arnsdorf, Germany
  • Aschaffenburg, Germany
  • Bamberg, Germany
  • Berlin - Hohenschonhausen, Germany
  • Berlin, Germany
  • Bernau, Germany
  • Bernburg, Germany
  • Bielefeld, Germany
  • Bonn, Germany
  • Butzbach, Germany
  • Celle, Germany
  • Dillingen, Germany
  • Dresden, Germany
  • Dusseldorf, Germany
  • Erbach, Germany
  • Essen, Germany
  • Giessen, Germany
  • Gottingen, Germany
  • Halle/Saale, Germany
  • Halle, Germany
  • Hamburg, Germany
  • Jena, Germany
  • Konigsbruck, Germany
  • Leipzig, Germany
  • Lengerich, Germany
  • Liegau-Augustusbad, Germany
  • Mittweida, Germany
  • Munster, Germany
  • Neukirchen-Vluyn, Germany
  • Neumunster, Germany
  • Oldenburg, Germany
  • Potsdam, Germany
  • Quickborn, Germany

Showing the first 100 of 231 sites across 24 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Pohlmann-Eden B, Marson AG, Noack-Rink M, Ramirez F, Tofighy A, Werhahn KJ, Wild I, Trinka E. Comparative effectiveness of levetiracetam, valproate and carbamazepine among elderly patients with newly diagnosed epilepsy: subgroup analysis of the randomized, unblinded KOMET study. BMC Neurol. 2016 Aug 23;16(1):149. doi: 10.1186/s12883-016-0663-7. PubMed 27552848 ↗
  • Trinka E, Marson AG, Van Paesschen W, Kalviainen R, Marovac J, Duncan B, Buyle S, Hallstrom Y, Hon P, Muscas GC, Newton M, Meencke HJ, Smith PE, Pohlmann-Eden B; KOMET Study Group. KOMET: an unblinded, randomised, two parallel-group, stratified trial comparing the effectiveness of levetiracetam with controlled-release carbamazepine and extended-release sodium valproate as monotherapy in patients with newly diagnosed epilepsy. J Neurol Neurosurg Psychiatry. 2013 Oct;84(10):1138-47. doi: 10.1136/jnnp-2011-300376. Epub 2012 Aug 29. PubMed 22933814 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2005, a primary completion of Oct 2007 and a completion of Oct 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2005
First posted
Sep 15, 2005
Start
Feb 2005
Primary completionActual
Oct 2007
CompletionActual
Oct 2007
Last update
Mar 17, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 17, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00175903
Lead sponsor
UCB Pharma
Responsible party
Sponsor
First posted
Sep 15, 2005
Start date
Feb 2005
Primary completion
Oct 2007
Completion
Oct 2007
Last update
Mar 17, 2015

Study contacts

UCB Clinical Trial Call Center
study director · UCB Pharma

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Levetiracetam

Start the discussion